Citation Impact
Citing Papers
Expert agreement confirms that negative changes in hand and foot radiographs are a surrogate for repair in patients with rheumatoid arthritis
2007
Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety
2008
Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?
2009
Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study
2013
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
2009
Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score
2005
The clinical efficacy and safety of certolizumab pegol in rheumatoid arthritis
2010
Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial
2009
Considerations with the use of biological therapy in the treatment of rheumatoid arthritis
2004
Predictors of joint damage in patients with early rheumatoid arthritis treated with high‐dose methotrexate with or without concomitant infliximab: Results from the ASPIRE trial
2006
Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis
2014
Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu
2010
Design of effective immunotherapy for human autoimmunity
2005 Nature
The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation
2009
The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events
2008
Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial
2006 Standout
Infections in patients with rheumatoid arthritis treated with biologic agents
2005
Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004
2004
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA
2010
Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate
2010
Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis
2006
Rheumatoid arthritis
2009
New therapies for treatment of rheumatoid arthritis
2007
Tuberculosis associated with therapy against tumor necrosis factor α
2005
Rheumatoid arthritis
2016 Standout
Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve‐month, multicenter, randomized, double‐blind, placebo‐controlled, phase II clinical trial
2008
Synovial Tissue Inflammation Mediated by Autoimmune T Cells
2019 StandoutNobel
Patients with Rheumatoid Arthritis Undergoing Surgery: How Should We Deal with Antirheumatic Treatment?
2007
Anti-TNF therapy: Where have we got to in 2005?
2005
Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD‐subgroup analyses across four randomized trials
2009
Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial
2010
Resistance of rheumatoid arthritis patients to changing therapy: Discordance between disease activity and patients' treatment choices
2007
Long‐term safety and efficacy of etanercept in children with polyarticular‐course juvenile rheumatoid arthritis
2006
The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double‐blind, placebo‐controlled phase IIa trial of three dosage levels of CP‐690,550 versus placebo
2009
Differentiating the efficacy of the tumor necrosis factor inhibitors
2005
Cytokine networks—towards new therapies for rheumatoid arthritis
2005
Comparative effectiveness of tumour necrosis factor α inhibitors in combination with either methotrexate or leflunomide
2009
The spectrum of latent tuberculosis: rethinking the biology and intervention strategies
2009 Standout
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
2013 Standout
A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal
2005
Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction
2011
Evidence that anti–tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: Extended report
2005
Juvenile idiopathic arthritis
2007 Standout
Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005
2005
Inflammatory bowel disease: clinical aspects and established and evolving therapies
2007 Standout
EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)
2006
TNF receptor 2 pathway: drug target for autoimmune diseases
2010
The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review
2007
Treatment of Idiopathic Pulmonary Fibrosis with Etanercept
2008
The Risk of Infections with Biologic Therapies for Rheumatoid Arthritis
2009
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial
2005
The Pathogenesis of Rheumatoid Arthritis
2011 Standout
Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: Results of a multicenter, randomized, double‐blind, active drug–controlled study
2008
Does tumor necrosis factor α inhibition promote or prevent heart failure in patients with rheumatoid arthritis?
2008
Modelling the cost effectiveness of TNF- antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry
2007
The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?
2008
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
2007
How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?
2014
Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
2013
How antirheumatic drugs protect joints from damage in rheumatoid arthritis
2008
Systematic Review and Meta-Analysis of the Efficacy and Safety of Existing TNF Blocking Agents in Treatment of Rheumatoid Arthritis
2012
Abatacept
2006
Forget personalised medicine and focus on abating disease activity
2012
A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness
2006
Cellular senescence in ageing: from mechanisms to therapeutic opportunities
2020 Standout
Adalimumab for long‐term treatment of psoriatic arthritis: Forty‐eight week data from the adalimumab effectiveness in psoriatic arthritis trial
2007
Glutamate neurotoxicity and diseases of the nervous system
1988 Standout
Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17–producing human T helper cells
2007 Standout
Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial
2008
Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group
2002 Standout
Improvement of Pharmacokinetic Profile of TRAIL via Trimer-Tag Enhances its Antitumor Activity in vivo
2017
Graphical Tools for Network Meta-Analysis in STATA
2013 Standout
IL-6 in Inflammation, Immunity, and Disease
2014 Standout
Rates of serious infection, including site‐specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register
2006
Avidin as a model for charge driven transport into cartilage and drug delivery for treating early stage post-traumatic osteoarthritis
2013 StandoutNobel
Interleukin-17 and Type 17 Helper T Cells
2009 Standout
Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges
2015
Superior efficacy of combination therapy for rheumatoid arthritis: Fact or fiction?
2005
Graves' Ophthalmopathy
2010 Standout
Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease‐modifying antirheumatic drug in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register
2006
Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis
2005
Ankylosing spondylitis
2007 Standout
Serious infections during anti-TNFα treatment in rheumatoid arthritis patients
2008
The immune response in atherosclerosis: a double-edged sword
2006 Standout
Differences in Reactivation of Tuberculosis Induced from Anti-TNF Treatments Are Based on Bioavailability in Granulomatous Tissue
2007
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
2011 Standout
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double‐blind, randomized, placebo‐controlled trial
2005
Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial
2007
Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha
2010
Functional Disability 5 Years after Acute Respiratory Distress Syndrome
2011 Standout
Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis
2004
Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison
2006
The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
2005
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial
2004
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
2012 Standout
Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study)
2016
Measuring finger joint cartilage by ultrasound as a promising alternative to conventional radiograph imaging
2009
Adalimumab in the therapy of uveitis in childhood
2006
Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate‐naive patients with active rheumatoid arthritis: Twenty‐four–week results of a phase III, multicenter, randomized, double‐blind, placebo‐controlled study of golimumab before methotrexate as first‐line therapy for early‐onset rheumatoid arthritis
2009
Rheumatoid arthritis
2010 Standout
Review of Eight Pharmacoeconomic Studies of the Value of Biologic DMARDs Adalimumab, Etanercept, and Infliximab) in the Management of Rheumatoid Arthritis
2006
BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies
2010
Functional Specialization of Interleukin-17 Family Members
2011 Standout
Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis
2008
Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study
2007
The pathogenesis of rheumatoid arthritis: new insights from old clinical data?
2012
A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview
2009
TREG-cell therapies for autoimmune rheumatic diseases
2014 StandoutNobel
Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called 'efficacy and safety' trials: a survey of power considerations
2008
The AMBITION trial: tocilizumab monotherapy for rheumatoid arthritis
2010
Cytokines in the pathogenesis of rheumatoid arthritis
2007 Standout
Inflammation, Atherosclerosis, and Coronary Artery Disease
2005 Standout
Recurrent miscarriage
2006 Standout
Idiopathic pulmonary fibrosis
2011 Standout
Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial
2013
Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example
2014
Targeting Toll-like receptors: emerging therapeutics?
2010
Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry
2005
The comparative effectiveness of tumor necrosis factor–blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: A six‐month, longitudinal, observational, multicenter study
2005
Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial
2004
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
2010 Standout
Double‐blind randomized controlled clinical trial of the interleukin‐6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate
2006
Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate
2008
Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies
2006 Standout
Rheumatoid Arthritis
2008
Synthesis of Heterobifunctional Protein Fusions Using Copper‐Free Click Chemistry and the Aldehyde Tag
2012 StandoutNobel
Inflammation in obesity, diabetes, and related disorders
2022 Standout
Tumor Necrosis Factor Inhibits Spread of Hepatitis C Virus Among Liver Cells, Independent From Interferons
2017 StandoutNobel
Dispensable roles of Gsdmd and Ripk3 in sustaining IL-1β production and chronic inflammation in Th17-mediated autoimmune arthritis
2021 StandoutNobel
Biologics in development for rheumatoid arthritis: Relevance to osteoarthritis☆
2006
Inflammatory bone loss: pathogenesis and therapeutic intervention
2012 Standout
Interleukin-6 inhibition for treatment of rheumatoid arthritis: A review of tocilizumab therapy
2010
The Simplified Disease Activity Index and Clinical Disease Activity Index to Monitor Patients in Standard Clinical Care
2009
Clinical Course and Prediction of Survival in Idiopathic Pulmonary Fibrosis
2010 Standout
Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis
2006
Predictive Ability of a Predischarge Hour-specific Serum Bilirubin for Subsequent Significant Hyperbilirubinemia in Healthy Term and Near-term Newborns
1999 Standout
Adalimumab in the Treatment of Rheumatoid Arthritis
2006
Methotrexate in Rheumatoid Arthritis
1987
Apoptosis: A Target for Anticancer Therapy
2018 Standout
Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine
1993 Standout
Engineering of monoclonal antibodies and antibody-based fusion proteins: successes and challenges
2005
Novel TNF antagonists for the treatment of rheumatoid arthritis
2009
Etanercept for the treatment of rheumatoid arthritis
2013
Etanercept for the Treatment of Rheumatoid Arthritis
2018
Global Molecular Effects of Tocilizumab Therapy in Rheumatoid Arthritis Synovium
2013
Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs
2014
Radiographic Measures to Assess Patients with Rheumatoid Arthritis: Advantages and Limitations
2009
Mechanisms of Diabetic Complications
2013 Standout
Factors Affecting Wound Healing
2010 Standout
Prosthetic Joint Infection
2014 Standout
TNF‐mediated inflammatory disease
2007 Standout
Systematic Review: Comparative Effectiveness and Harms of Disease-Modifying Medications for Rheumatoid Arthritis
2008
Osteoarthritis: an update with relevance for clinical practice
2011 Standout
Sjögren's syndrome. Proposed criteria for classification
1986
Impaired T cell receptor signaling and development of T cell–mediated autoimmune arthritis
2020 StandoutNobel
Industry sponsorship and research outcome
2017 Standout
The likelihood ratio. An improved measure for reporting and evaluating diagnostic test results.
1986
Immunogenic Cell Death in Cancer Therapy
2012 Standout
Integrating mechanisms of pulmonary fibrosis
2011 Standout
Works of J Jäger being referenced
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
2004
Salivary scanning in rheumatoid arthritis with sicca syndrome.
1984